Fact CheckerSign in

NCT06831331Enrolling by invitation

Nutrition in Rheumatoid Arthritis

NUTRA- Nutrition in Rheumatoid Arthritis

Source: ClinicalTrials.gov · Last updated 23 Oct 2026

Brief summary (registry, in English)

Background: Individuals with Rheumatoid Arthritis (RA) often experience persistent symptoms such as pain and stiffness despite modern pharmacological treatments. They also have an increased risk of cardiovascular disease. Elevated risk factors for cardiovascular disease limit the options for some symptom-relieving medications, making a reduction in these risk factors highly desirable. Diet has been shown to reduce several of these factors, but the scientific evidence for rheumatoid arthritis is limited, and thus tailored dietary advice is lacking. Objective: The purpose of the NUTRA study is to evaluate the effect of a diet that follows the updated Nordic Nutrition Recommendations (2023) on disease activity and cardiovascular risk factors in individuals with diagnosed RA. Specifically, the study will analyze the impact of the diet on clinically relevant markers such as blood pressure, lipid profile, inflammatory markers, and body composition. Study Plan: The study will include about 120 patients, and participants will be randomized into either an immediate 3-month diet intervention following the Nordic Nutrition recommendations or a waitinglist control group, that will start with the diet intervention after three months. The intervention diet, will be added as a complementary treatment to the medications the patients are already taking. Participants will receive menus, recipes and some foods for three months, followed by self-maintenance of the diet. Clinical markers will be evaluated before and after the intervention/control periods and six months after ending their intervention period. Primary outcome is ApoB. The NUTRA study aims to generate evidence to guide the design of dietary interventions for patients with rheumatoid arthritis. By understanding the potential role of diet in reducing both disease activity and cardiovascular risk, the study may contribute to improved treatment strategies for this challenging patient group.

Status (registry)
Enrolling by invitation
Study type
Interventional
Enrollment
120 (estimated)
First submitted
27 Jan 2025
Start date
25 Feb 2025
Primary completion date
31 Dec 2028
Lead sponsor
Vastra Gotaland Region
NCT number
NCT06831331

What you commit to

  • Study type: Interventional
  • Planned participants: 120
  • From 25 Feb 2025 to the primary completion date, 31 Dec 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • diagnosis for cancer or other life-threatening diseases
  • diabetes type 1 and 2
  • inflammatory bowel disease or celiac disease

Other

  • pregnancy
  • lactation

Who the study is looking for

  • diagnosed RA on Methotrexate and/or additional treatment. RA is defined according to the criteria from EULAR/American College of Rheumatology (ACR) 2010.
  • BMI 18.5-40 kg/m2
  • willing to follow the intervention diet

Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Klinisk Reumatologiskt Forskningscentrum, Sahlgrenska University Hospital
Coordinator of this site? Confirm its status
GothenburgSwedenUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.